id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2018-N-3091-0004,FDA,FDA-2018-N-3091,Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal; Correction,Notice,Correction,2023-01-11T05:00:00Z,2023,1,2023-01-11T05:00:00Z,,2023-01-11T14:43:10Z,2023-00390,0,0,09000064855e05c7
FDA-2018-N-3091-0003,FDA,FDA-2018-N-3091,Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal,Notice,Notice of Renewal,2022-12-13T05:00:00Z,2022,12,2022-12-13T05:00:00Z,,2022-12-13T16:40:16Z,2022-27014,0,0,0900006485532499
FDA-2018-N-3091-0002,FDA,FDA-2018-N-3091,"Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee;
Renewal",Notice,Renewals,2020-09-29T04:00:00Z,2020,9,2020-09-29T04:00:00Z,,2020-09-29T17:53:41Z,2020-21465,0,0,0900006484898778
FDA-2018-N-3091-0001,FDA,FDA-2018-N-3091,"Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee;
Renewal",Notice,Renewals,2018-09-04T04:00:00Z,2018,9,2018-09-04T04:00:00Z,,2018-10-23T15:25:37Z,2018-19067,0,0,090000648369499c